INT20082

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.29
First Reported 1985
Last Reported 2009
Negated 0
Speculated 1
Reported most in Abstract
Documents 6
Total Number 8
Disease Relevance 4.27
Pain Relevance 3.03

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular region (PRLR) plasma membrane (PRLR)
Anatomy Link Frequency
GPI 1
PRLR (Homo sapiens)
Pain Link Frequency Relevance Heat
Potency 6 100.00 Very High Very High Very High
antagonist 12 99.74 Very High Very High Very High
Dopamine 20 99.52 Very High Very High Very High
opioid receptor 5 98.86 Very High Very High Very High
Buprenorphine 10 97.60 Very High Very High Very High
agonist 13 96.52 Very High Very High Very High
Opioid 3 95.48 Very High Very High Very High
opiate 5 95.04 Very High Very High Very High
Morphine 2 93.84 High High
Nucleus accumbens 1 81.36 Quite High
Disease Link Frequency Relevance Heat
Galactorrhea 96 100.00 Very High Very High Very High
Systemic Lupus Erythematosus 102 99.96 Very High Very High Very High
Congenital Anomalies 12 94.88 High High
Glioma 1 93.48 High High
Neuroblastoma 1 93.20 High High
Reprotox - General 1 4 92.00 High High
Disease 18 90.92 High High
Hypothyroidism 4 88.16 High High
Hypophysis Disease 4 85.88 High High
Renal Failure 4 82.80 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Pediatric HPRL SLE patients without ?
Positive_regulation (Pediatric) of HPRL associated with galactorrhea and systemic lupus erythematosus
1) Confidence 0.29 Published 2009 Journal Pediatr Rheumatol Online J Section Body Doc Link PMC2770548 Disease Relevance 2.18 Pain Relevance 0
Risperidone, a dopamine antagonist is known to induce HPRL, however, the mean half-life of risperidone and its active metabolite, 9-hydroxyrisperidone, is 20 hours with a range from 21 to 30 hours.
Positive_regulation (induce) of HPRL associated with galactorrhea, dopamine and antagonist
2) Confidence 0.27 Published 2009 Journal Pediatr Rheumatol Online J Section Body Doc Link PMC2770548 Disease Relevance 1.76 Pain Relevance 0.10
Surprisingly, when the reciprocal mutations, Lys-214 --> Ala (TM5), Ile-277 --> Val/His-278 --> Gln/Ile-279 --> Val (TM6), and Ile-304 --> Thr (TM7), are introduced in the delta receptor, neither the individual mutations nor their various combinations significantly reduce the binding affinities of opioid alkaloids tested.
Positive_regulation (introduced) of delta receptor associated with opioid
3) Confidence 0.03 Published 2000 Journal J. Biol. Chem. Section Abstract Doc Link 10777506 Disease Relevance 0 Pain Relevance 0.65
During metaclopramide infusion, a similar increment in hPRL was observed during acute PRL release.
Positive_regulation (increment) of hPRL
4) Confidence 0.03 Published 1990 Journal J. Clin. Endocrinol. Metab. Section Abstract Doc Link 2118537 Disease Relevance 0.07 Pain Relevance 0.24
The results of these studies define specific structural features of these compounds responsible for opioid receptor interactions and suggest a possibly novel mechanism for delta receptor activation.
Positive_regulation (activation) of delta receptor associated with opioid receptor
5) Confidence 0.01 Published 1996 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 8667189 Disease Relevance 0 Pain Relevance 0.19
These results suggest that the principle factor determining increases in potency of novel delta receptor ligands to date is an increase in receptor affinity.
Spec (determining) Positive_regulation (increases) of delta receptor associated with potency
6) Confidence 0.00 Published 1993 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 8394911 Disease Relevance 0 Pain Relevance 0.34
(however, the relative potencies were higher in the MVD assay then predicted on the basis of binding affinities); (3) the DTE series also showed an increase in delta receptor affinities and MVD potencies relative to DALEA, for n = 2-12; (4) for the DTE series, the increase in MVD activities was less than that expected on the basis of delta binding affinity; (5) for both the DPE and DTE series, activities in the GPI assay and mu-receptor affinities were highly correlated: as the length of the methylene bridge increased from 2 to 12, there was a progressive loss of activity in both assays, with a similar pattern for DPE and DTE.
Positive_regulation (increase) of delta receptor in GPI
7) Confidence 0.00 Published 1985 Journal Biochem. Pharmacol. Section Abstract Doc Link 2981528 Disease Relevance 0.19 Pain Relevance 0.43
At the kappa receptor level, repeated administration of CRZ acted only on Kd, whereas the delta receptor was up-regulated.
Positive_regulation (up-regulated) of delta receptor
8) Confidence 0.00 Published 2005 Journal Brain Res. Section Abstract Doc Link 16269137 Disease Relevance 0.07 Pain Relevance 1.08

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox